Elicit: Lipid Nanoparticles in mRNA Vaccine Delivery
Lipid Nanoparticles in mRNA Vaccine Delivery
How do lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccine antigens?
Lipid nanoparticles (LNPs) deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines by encapsulating the mRNA through electrostatic and hydrogen bonding interactions, facilitating cellular uptake via endocytosis, and releasing the mRNA into the cytoplasm when ionizable lipids protonate in acidic endosomes and disrupt the endosomal membrane to enable translation.
Abstract
Lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines through a coordinated physicochemical and biological process. LNPs composed of ionizable lipids, helper lipids, cholesterol, and PEG-lipids form 50-85 nm particles that encapsulate mRNA via electrostatic interactions and hydrogen bonding. Following intramuscular administration, LNPs are taken up by muscle-resident immune cells through endocytosis, with >10% of myeloid and lymphoid cells successfully transduced. The critical delivery step occurs when ionizable lipids protonate in acidic endosomes (pH ~5-6), triggering ion pairing with endosomal phospholipids that disrupts membranes and releases mRNA into the cytoplasm. Nucleoside modifications such as m1ψ reduce innate immune recognition of the mRNA cargo, while optimized formulations achieve 93-95% encapsulation efficiency and mRNA detectability for 14-28 days post-vaccination in humans.
Beyond mRNA delivery, LNPs function as intrinsic adjuvants by triggering rapid neutrophil and dendritic cell recruitment within 24 hours and inducing IL-6 production critical for germinal center responses. This dual functionality produces potent immunogenicity, with optimized formulations achieving 10-fold higher neutralizing titers than standard LNPs and protective immunity at doses as low as 0.25 µg. Rational lipid design enables independent control of delivery efficiency, tissue targeting, immune activation, and stability: the C24 formulation reduces off-target liver expression 6-fold while maintaining potency, adjuvant lipidoids provide TLR7/8 activation, and specific formulations remain stable at 4°C for at least 19 days. These mechanisms collectively explain the exceptional clinical efficacy of LNP-mRNA SARS-CoV-2 vaccines.
Methods
We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.
Screening Criteria
- Lipid Nanoparticle Delivery System: Does this study investigate lipid nanoparticles (LNPs) as delivery vehicles for mRNA?
- Nucleoside-Modified mRNA: Does this study involve nucleoside-modified mRNA (such as pseudouridine-modified or other nucleoside modifications)?
- SARS-CoV-2 Antigen Target: Does the mRNA in this study encode SARS-CoV-2 antigens rather than non-SARS-CoV-2 antigens?
- Delivery Mechanism Data: Does this study report on delivery mechanisms, cellular uptake, biodistribution, or pharmacokinetics of LNP-mRNA systems?
- Study Type: Is this a preclinical study or clinical study rather than an opinion piece or editorial?
- Delivery System Scope: Does this study focus on lipid-based delivery systems rather than non-lipid delivery systems?
Data Extraction Details
- LNP Composition: Extract details on ionizable lipids, helper lipids, cholesterol, PEG-lipids, design rationale, particle size, and formulation buffer.
- mRNA Specifications: Extract characteristics of mRNA including target antigens, nucleoside modifications, sequence length, cap structure, and optimization strategies.
- Cellular Uptake Mechanism: Extract details of how LNPs deliver mRNA including cell types, uptake pathways, endosomal escape mechanisms, and protein expression timeline.
- Delivery Efficiency: Extract measures of mRNA delivery effectiveness including protein expression levels, transfection efficiency, duration of protein expression, and tissue specificity.
- Structural Properties: Extract characteristics such as LNP morphology, membrane organization, mechanical properties, and observations from structural studies.
- Biodistribution Pattern: Extract biodistribution data showing target tissues, distribution kinetics, and clearance mechanisms.
- Inflammatory Effects: Extract data on innate immune responses, cytokine induction, and inflammatory responses.
- Stability Factors: Extract factors affecting LNP-mRNA stability over time including storage temperature and degradation mechanisms.
Results
Characteristics of Included Studies
| Study | Full text retrieved? | Study focus | LNP formulation | Study design |
|---|---|---|---|---|
| Suman Alishetty et al., 2021 | Yes | Novel C24 ionizable lipid development | C24 lipid (48:13:37:2 ratio) | Mouse immunogenicity and challenge studies |
| Afshana Quadiri et al., 2024 | Yes | Effect of helper lipid composition | LNP4 with DOPE phospholipid | Hamster protection studies comparing 4 LNP formulations |
| Afshana Quadiri et al., 2025 | Yes | DOPE-containing LNP characterization | LNP4 with DOPE | Hamster immunogenicity and protection |
| Xuexiang Han et al., 2023 | Yes | Adjuvant lipidoid substitution | C12-TLRa adjuvant lipidoid | Mouse immunogenicity with TLR7/8 agonist lipid |
| J. Szebeni et al., 2023 | Yes | Structural analysis of Comirnaty vaccine | BNT162b2 with ALC-0315 | Physicochemical characterization using AFM, cryo-TEM |
| S. Kent et al., 2024 | No | Human pharmacokinetics | Moderna SPIKEVAX | Clinical study in 19 vaccinated subjects |
| M. Alameh et al., 2021 | Yes | Adjuvant activity mechanisms | Proprietary Acuitas formulation | Mouse studies with influenza and SARS-CoV-2 mRNA |
| Natalia Martinez et al., 2025 | No | Monoolein as helper lipid | MO-based modified Moderna LNPs | In vivo delivery efficiency studies |
| Dorottya Laczkó et al., 2020 | Yes | Nucleoside-modified mRNA immunogenicity | Standard LNP formulation | Mouse single-dose immunogenicity |
| Devdoot Majumdar et al., 2023 | No | Mechanisms of muscle-based adjuvancy | Moderna sm-102 formulation | Mouse mechanistic studies of immune response |
LNP Composition and Formulation Design
LNP formulations for SARS-CoV-2 mRNA delivery consist of four core lipid components: ionizable lipids, helper lipids, cholesterol, and PEG-lipids. The ionizable lipid component is critical for mRNA complexing and pH-dependent release.
| Component | Example formulations | Molar ratios | Design rationale |
|---|---|---|---|
| Ionizable lipid | C24, ALC-0315, C12-TLRa | 35-48% | Enhanced endosomal protonation; TLR7/8 activation |
| Helper lipid | DSPC, DOPC, DOPE, Monoolein | 13-16% | Structural stability; pH-dependent mesophase transitions |
| Cholesterol | Standard component | 37-46.5% | Structural support |
| PEG-lipid | DMG-PEG2000 | 2-2.5% | Immune evasion and circulation |
The C24 LNP formulation demonstrated a specific composition of 48:13:37:2 for ionizable lipid/DSPC/cholesterol/DMG-PEG2000, formulated in PBS at pH 7.3-7.4. The adjuvant lipidoid formulation used a 35:16:46.5:2.5 ratio and achieved a particle size of approximately 52 nm with low polydispersity (PDI 0.127).
mRNA Cargo Characteristics
The nucleoside-modified mRNA cargo encoded the SARS-CoV-2 spike protein with specific structural modifications.
| mRNA feature | Specifications |
|---|---|
| Nucleoside modification | m1ψ (1-methylpseudouridine); Pseudo-U; m1J-5’-triphosphate |
| Sequence length | 3,804 bp; 4,284 nucleotides |
| Cap structure | Trinucleotide cap1 analog (CleanCap) |
| Poly-A tail | 80-101 adenine residues |
| Codon optimization | Applied to enhance translation |
| Encapsulation efficiency | 93-95% |
Cellular Uptake and Delivery Mechanisms
LNPs deliver mRNA through a multi-step process involving cellular uptake, endosomal escape, and cytoplasmic release. The ionizable lipids play a central role in pH-dependent delivery.
Uptake pathways and cell types:
Muscle-resident myeloid and lymphoid cells were directly transduced, with >10% of these cells successfully receiving mRNA.
Endosomal escape mechanism:
The cellular uptake occurred via endocytosis. Following endocytosis, ionizable lipids became protonated in the acidic endosomal environment. This protonation triggered ion pairing with endosomal phospholipids to open the endosomal membrane.
Delivery Efficiency and Protein Expression
Quantitative delivery efficiency varied across formulations, with several showing superior performance compared to standard formulations.
Biodistribution Patterns
Following intramuscular administration, LNPs demonstrated specific biodistribution kinetics with varying degrees of systemic exposure.
Immune Activation and Adjuvant Properties
Beyond mRNA delivery, LNPs demonstrated intrinsic adjuvant activity contributing to robust immune responses.
Stability and Storage Considerations
LNP-mRNA stability depended critically on storage temperature and formulation design.
Synthesis
The mechanisms by which lipid nanoparticles deliver nucleoside-modified mRNA for SARS-CoV-2 vaccines involve an integrated series of physicochemical and biological processes.